Optimizing the HC/LC chain ratio can significantly enhance production efficiency and purity. 8 When needed, we can conduct chain ratio studies to achieve higher expression titers and improved heterodimer purity.
Figure 10. This case study focuses on a scFv-Fab with three chains: a LC, a HC1 and a HC2. The initial transfection ratio of HC1:HC2:LC at 2:1:1 resulted in low titer and limited heterodimer percentage. By increasing HC1 ratio, we significantly improved heterodimer purity from 12% to 72%.
Conclusion Bispecific antibodies continue to drive therapeutic innovations by offering highly targeted and effective treatments. Leveraging extensive drug development expertise, we employ innovative strategies tailored to various bsAb formats to achieve superior purity and quality in bsAb production. These approaches ensure the consistent delivery of high-quality bsAbs, contributing to the advancement of drug development.
References
1. Herrera M., Pretelli G., Desai J., Garralda E., Siu L. L., Steiner T. M., Au L. Bispecific antibodies: advancing precision oncology. Trends Cancer . 2024;10(10):893-919. doi: 10.1016/j.trecan.2024.07.002. 2. Ma J., Mo Y., Tang M., Shen J., Qi Y., Zhao W., Huang Y., Xu Y., Qian C. Bispecific Antibodies: From Research to Clinical Application. Front Immunol . 2021;12:626616. doi: 10.3389/fimmu.2021.626616. 3. Sun Y., Yu X., Wang X., Yuan K., Wang G., Hu L., Zhang G., Pei W., Wang L., Sun C., Yang P. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B . 2023;13(9):3583-3597. doi: 10.1016/j.apsb.2023.05.023. 4. Hofmann T., Krah S., Sellmann C., Zielonka S., Doerner A. Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies. Int J Mol Sci . 2020;21(18):6551. doi: 10.3390/ijms21186551. 5. Chen S. W., Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther . 2021;4(2): 73-88. doi: 10.1093/abt/tbab007. 6. Ridgway J. B., Presta L. G., Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng . 1996;9(7):617-21. doi: 10.1093/protein/9.7.617. 7. Mullin M., McClory J., Haynes W., Grace J., Robertson N., van Heeke G. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. mAbs . 2024;16(1):2341443. doi: 10.1080/19420862.2024.2341443. 8. Haryadi R., Ho S., Kok Y. J., Pu H. X., Zheng L., Pereira N. A., Li B., Bi X., Goh L. T., Yang Y., Song Z. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS One . 2015;10(2):e0116878. doi: 10. 1371/journal.pone.0116878.
About WuXi Biologics WuXi Biologics is a leading contract research, development, and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.
The world’s leading global single-source platform from concept to commercialization wuxibiologics.com PS_Marketing@wuxibiologics.com
wuxibiologics.com 6
Powered by FlippingBook